文献速递肝胆胰外科

肝细胞癌门静脉癌栓生长速度及其影响因素研究

Growth velocity of the portal vein tumor thrombus accelerated by its progression, alpha-fetoprotein level, and liver fibrosis stage in patients with hepatocellular carcinoma.
PubMed 文献 · Surgery · 2018-08-06

该回顾性研究纳入2005至2015年间57例术前两次CT检查后行肝切除术的肝细胞癌合并门静脉癌栓患者,按癌栓生长速度分为快速组(≥1.0 mm/day,n=23)与缓慢组(<1.0 mm/day,n=34),分析癌栓生长速度及其危险因素,以探讨合适的手术时机。

要点

  • 门静脉癌栓平均生长速度为0.9±1.0 mm/day,快速生长者预后需关注。
  • 肝纤维化、甲胎蛋白及癌栓累及范围是癌栓快速进展的独立危险因素。
  • PIVKA-II、癌栓累及范围及肝纤维化是独立预后因素,而非癌栓快速生长。

核心结论

  • 理解门静脉癌栓的快速进展及其危险因素有助于决定肝细胞癌合并门静脉癌栓的手术治疗时机。

研究设计与样本

  • 回顾性研究,纳入2005至2015年间57例术前两次CT检查后行肝切除术的肝细胞癌合并门静脉癌栓患者。
  • 以癌栓迁移长度除以天数计算生长速度,按≥1.0 mm/day(n=23)与<1.0 mm/day(n=34)分组。

主要发现

  • 癌栓侵犯同侧第二门静脉支、同侧第一门静脉支和门静脉主干患者的中位生存时间分别为42.9、11.7和12.3个月。
  • 门静脉癌栓平均生长速度为0.9±1.0 mm/day。
  • 从同侧第二门静脉支进展至同侧第一门静脉支、从同侧第一门静脉支进展至门静脉主干的中位估计时间分别为8.2和11.5天。
  • 肝纤维化、甲胎蛋白和癌栓累及范围是癌栓快速进展的独立危险因素。
  • PIVKA-II、癌栓累及范围和肝纤维化是独立预后因素,癌栓快速生长不是独立预后因素。

临床怎么用

  • 对肝细胞癌合并门静脉癌栓患者,可结合肝纤维化、甲胎蛋白及癌栓累及范围评估癌栓快速进展风险,辅助决定手术时机。

局限性

  • 回顾性研究,样本量57例,来自单中心2005至2015年数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Progression of portal vein tumor thrombus directly affects the prognosis and treatment for patients with hepatocellular carcinoma; there are no data on the growth velocity of portal vein tumor thrombus. We analyzed the growth velocity of portal vein tumor thrombus and its risk factors to propose the best timing of surgical treatment for hepatocellular carcinoma with portal vein tumor thrombus. METHODS: We retrospectively collected data on 57 hepatocellular carcinoma patients with portal vein tumor thrombus who underwent computed tomography twice preoperatively and hepatectomy between 2005 and 2015. To calculate the growth velocity of portal vein tumor thrombus, migration lengths of portal vein tumor thrombus were divided by the number of days. To identify risk factors for rapid growth of portal vein tumor thrombus, patients were classified according to the velocity: rapid (≥ 1.0 mm/day, n = 23) and slow (< 1.0 mm/day, n = 34). RESULTS: Median survival times of patients with portal vein tumor thrombus that invaded the ipsilateral second portal branch, ipsilateral first portal branch, and portal trunk were 42.9, 11.7, and 12.3 months, respectively. The average growth velocity of portal vein tumor thrombus was 0.9 ± 1.0 mm/day. Median estimated times required from ipsilateral second portal branch to ipsilateral first portal branch and ipsilateral first portal branch to portal trunk were 8.2 and 11.5 days, respectively. Liver fibrosis, alpha-fetoprotein, and extent of portal vein tumor thrombus were independent risk factors for rapid progression of portal vein tumor thrombus. Proteins induced by vitamin K absence or antagonist II, extent of portal vein tumor thrombus, and liver fibrosis, not rapid growth of portal vein tumor thrombus, were independent prognostic factors. CONCLUSION: An understanding of the rapid progression of portal vein tumor thrombus and its risk factors can be helpful in deciding an appropriate timing of surgical treatment for hepatocellular carcinoma with portal vein tumor thrombus.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Gon H, Kido M, Tanaka M, et al. Growth velocity of the portal vein tumor thrombus accelerated by its progression, alpha-fetoprotein level, and liver fibrosis stage in patients with hepatocellular carcinoma. Surgery. 2018. PMID: 30093272. doi:10.1016/j.surg.2018.06.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。